Analyst Says MedMen's Momentum Changing, Tilray's Stake Won't Double Its Value But Will Hold Premium

MedMen Enterprises Inc. (OTCQX: MMNFF) revealed Tuesday that it has secured $100 million in financing via a private sale of its units in a deal led by Serruya Private Equity.

At the same time, the company disclosed that Tilray, Inc. (NASDAQ: TLRY) acquired the majority of MedMen’s outstanding senior secured convertible notes that were originally held by certain funds affiliated with Gotham Green Partners LLC (GGP) and others.

The Analyst

Cantor Fitzgerald analyst Pablo Zuanic upgraded his rating on MedMen’s stock from Underweight to Neutral and established a price target of $0.30.

The Thesis

Tilray is around $118 million in MedMen …

Full story available on Benzinga.com

More Analyst Says MedMen's Momentum Changing, Tilray's Stake Won't Double Its Value But Will Hold Premium